Navigation Links
Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections
Date:6/8/2009

al," said Jeffrey Stein, Ph.D., Chief Executive Officer of Trius. "Later this year we will complete Phase 1 testing of the IV dosage form of torezolid and plan to merge the oral and IV programs in Phase 3 testing early next year. Our aim is to make torezolid available to physicians and patients as soon as possible to address the growing unmet medical need for an effective and well tolerated new IV and oral treatment for drug-resistant infections."

About Torezolid (TR-701)

Torezolid is a second-generation IV/oral antibacterial drug in the oxazolidinone class. It is significantly differentiated from Zyvox(R) (linezolid), the only marketed drug in this class. Advantages of torezolid over linezolid include:

  • 4-8 fold greater potency than linezolid in vitro and in vivo
  • In vivo bactericidal activity
  • Activity against all clinically important, gram-positive, drug-resistant strains including those resistant to linezolid
  • Activity against clinically important atypical and gram-negative pathogens (Legionella, Chlamydia, Neisseria)
  • 16x lower rate of resistance development in MRSA
  • Once-daily and shorter course of therapy to promote better treatment compliance
  • Broader safety window enabling potential longer course of therapy
  • Possibility for expanded indications including bacteremia, severe CAP and osteomyelitis
  • Lower potential for drug-drug interactions including those with dietary tyramine, SSRIs and vasoconstrictors

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company's lead drug candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity agai
'/>"/>

SOURCE Trius Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
2. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
3. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
4. Trius Doses First Patient in Antibacterial Phase 2 Trial
5. PacificGMP Completes GMP Product Fill for Trius Therapeutics
6. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
7. Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
8. Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes
9. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
10. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
11. Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 18, 2013 Valeant Pharmaceuticals International, ... (the "Company") announced today that VPII Escrow Corp., a ... has launched its offer of approximately $3.2 billion aggregate ... Notes will be due in 2021 and in 2023, ... Company intends to use the net proceeds from the ...
(Date:6/18/2013)... ROCKY HILL, Conn. , June 18, 2013 ... many past clients of Alliance Seating and Mobility, ... now unable to access timely repair. This appears ... and a dramatic reduction of field service employees.  ... Unfortunately a great many of these clients ...
(Date:6/18/2013)... , June 18, 2013  Cataracts are the leading ... American Association of Ophthalmology, aging is the leading cause ... the eye,s natural lens. 22 million Americans age 40 ... Boomers continue to age, that number will increase over ... of iPhones, iPads, smart-phones and computers, the demographic of ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3New Vision Hope For Millions Undergoing Cataract Surgery 2New Vision Hope For Millions Undergoing Cataract Surgery 3
... (NYSE: LLY ) will present data from more ... American Society of Clinical Oncology (ASCO) in Chicago, Ill., from ... Phase III study of an ALIMTA-based continuation maintenance regimen for ... data will be included in the ASCO-sponsored press briefing the ...
... Systems Inc. (OTCBB: PLCSF), a company focused on innovative ... three- month period ended March 31, 2011. These results ... the sale of its transmyocardial revascularization (TMR) business to ... from the TMR business for the first quarter of ...
Cached Medicine Technology:Lilly Oncology to Unveil Data From More Than 30 Studies at ASCO 2PLC Systems Reports First Quarter 2011 Results 2PLC Systems Reports First Quarter 2011 Results 3PLC Systems Reports First Quarter 2011 Results 4PLC Systems Reports First Quarter 2011 Results 5PLC Systems Reports First Quarter 2011 Results 6PLC Systems Reports First Quarter 2011 Results 7
(Date:6/18/2013)... 2013 The Drug Delivery Partnering Terms ... to the drug delivery partnering deals and agreements entered ... The report provides a detailed understanding and analysis of ... The majority of deals are discovery or development stage ... right to license the license drug delivery technology. These ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 Senior drug regulatory ... on June 25 to discuss—for the first time in the ... getting drugs through the regulatory process in a timely manner. ... evaluation will share respective best practices and processes in drug ... Strait panel at the DIA 2013 49th Annual ...
(Date:6/18/2013)... Biomet hip lawsuit claims ... in a multidistrict litigation in U.S. District Court, Northern ... to court records, the litigation’s most recent status conference ... Court also convened a motions hearing and a tutorial ... Biomet hip replacement litigation. The proceeding’s next Status ...
(Date:6/18/2013)... Dallas, TX (PRWEB) June 18, 2013 ... Tebbetts, launched his new website, thebestbreast.com, showcasing his ... provides women with information about his surgical method ... , Outlined on his website, Dr. Tebbetts ... Unlike the traditional methods, Dr. Tebbetts’ method does ...
(Date:6/18/2013)... using technology developed at Case Western Reserve University,s ... of Engineering, has made available avatarsvirtual patientsto train ... and others training to evaluate speech-language disorders to ... on the trainee, because a diagnosis doesn,t have ... , Graduate students studying to become speech-language pathologists ...
Breaking Medicine News(10 mins):Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 2Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 3Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 4Health News:Renowned Regulatory Representatives From Mainland China and Taiwan to Discuss Need for Collaboration at DIA Meeting 2Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 2Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 3Health News:Internationally Acclaimed Breast Augmentation Expert Announces the Launch of His New Website 2Health News:SimuCase avatars advance speech-language pathology training 2
... RATON, Fla., Sept. 26 Biomedtex Inc.,(Pink Sheets: ... company, announced today that A. Marc Rocca, 42, ... The Company,s mission is to identify, evaluate ... and healthcare solutions, and then,seek to capture and ...
... Consider Proposals and Variations, LOS ANGELES, ... ISCR) a leading e-health Wi-Fi PDA technology ... DME and EMR applications,and the distributor of ... surgical products, announced today that its Board ...
... North America in Deal Valued at up ... to $185 ... 26, NPS Pharmaceuticals, Inc. (Nasdaq: NPSP ) and,Nycomed announced ... to Nycomed the rights to develop and commercialize,GATTEX(TM) (teduglutide) outside ...
... ultrasound-guided fine needle to biopsy lymph nodes could spare ... to undergo unnecessary and sometimes unpleasant surgery to verify ... , In a study presented today (Wednesday) at the ... that the less invasive technique produced a false positive ...
... Barcelona, Spain: New research has yielded a clearer picture ... the treatment of colon cancer, bringing closer the day ... spared it, while those that will, get the more ... other solid tumours, doctors plan treatment of colon cancer ...
... to use for older people is the focus of a ... in funding in the latest round of the Australian Research ... design researcher Dr Thea Blackler, is one of 24 projects ... announcement tops off a successful week for QUT research, with ...
Cached Medicine News:Health News:InstaCare Corp. Reviewing M&A Plans 2Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 2Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 3Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 4Health News:Less invasive lymph node biopsy method could spare thousands unnecessary operations 2Health News:Study makes progress in zoning in on biomarkers for better colon cancer treatment 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: